Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Self-assembly of block copolymers during hollow fiber spinning: an in situ small-angle X-ray scattering study.

Sankhala K, Wieland DCF, Koll J, Radjabian M, Abetz C, Abetz V.

Nanoscale. 2019 Apr 23;11(16):7634-7647. doi: 10.1039/c8nr06892e.

PMID:
30698584
2.

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.

Sankhala K, Takimoto CH, Mita AC, Xiong H, Rodón J, Mehrvarz Sarshekeh A, Burns K, Iizuka K, Kopetz S.

Invest New Drugs. 2019 Feb;37(1):76-86. doi: 10.1007/s10637-018-0602-0. Epub 2018 Apr 18.

PMID:
29667134
3.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.

Mita MM, Mita AC, Moseley JL, Poon J, Small KA, Jou YM, Kirschmeier P, Zhang D, Zhu Y, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig SJ, Bannerji R, Shapiro GI.

Br J Cancer. 2017 Oct 24;117(9):1258-1268. doi: 10.1038/bjc.2017.288. Epub 2017 Aug 31.

4.

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.

Eur J Cancer. 2017 May;76:118-124. doi: 10.1016/j.ejca.2017.01.028. Epub 2017 Mar 17.

PMID:
28324746
5.

Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.

Sankhala KK.

Expert Opin Investig Drugs. 2017 Apr;26(4):427-443. doi: 10.1080/13543784.2017.1303045. Epub 2017 Mar 20. Review.

PMID:
28267385
6.

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.

Gordon EM, Sankhala KK, Chawla N, Chawla SP.

Adv Ther. 2016 Jul;33(7):1055-71. doi: 10.1007/s12325-016-0344-3. Epub 2016 May 27. Review.

7.

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.

Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ.

JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol.2015.3101.

PMID:
26378637
8.

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ.

Cancer. 2015 Feb 15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13.

9.

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.

Mahalingam D, Nemunaitis JJ, Malik L, Sarantopoulos J, Weitman S, Sankhala K, Hart J, Kousba A, Gallegos NS, Anderson G, Charles J, Rogers JM, Senzer NN, Mita AC.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1241-50. doi: 10.1007/s00280-014-2602-x. Epub 2014 Oct 11.

PMID:
25304209
10.

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.

Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, Benjamin D, Ketchum N, Michalek J, Tolcher A, Wright J, Sarantopoulos J.

Cancer Chemother Pharmacol. 2014 Jul;74(1):77-84. doi: 10.1007/s00280-014-2479-8. Epub 2014 May 10.

PMID:
24817603
11.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, Statkevich P, Zhu Y, Yao SL, Small K, Bannerji R, Shapiro CL.

Clin Breast Cancer. 2014 Jun;14(3):169-76. doi: 10.1016/j.clbc.2013.10.016. Epub 2013 Oct 26.

PMID:
24393852
12.

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.

Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, Sarantopoulos J, Sankhala K, Mendelson D.

Target Oncol. 2014 Sep;9(3):215-24. doi: 10.1007/s11523-013-0288-3. Epub 2013 Jul 6.

PMID:
23832397
13.

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

Sikaria S, Heim-Hall J, Diaz EH, Williams R, Sankhala K, Laabs B, Mita M.

Target Oncol. 2014 Mar;9(1):73-9. doi: 10.1007/s11523-013-0267-8. Epub 2013 Feb 21. No abstract available.

PMID:
23430345
14.

Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.

Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, Sankhala K, Mita A, Elian K, Bouchard D, Sarantopoulos J.

Mol Cancer Ther. 2012 Feb;11(2):308-16. doi: 10.1158/1535-7163.MCT-11-0566. Epub 2011 Dec 27.

15.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD.

J Clin Oncol. 2012 Jan 1;30(1):78-84. doi: 10.1200/JCO.2011.35.6329. Epub 2011 Nov 7. Erratum in: J Clin Oncol. 2017 Aug 10;35(23):2722.

PMID:
22067397
16.

Heat shock proteins: a potential anticancer target.

Sankhala KK, Mita MM, Mita AC, Takimoto CH.

Curr Drug Targets. 2011 Dec;12(14):2001-8. Review.

PMID:
21777196
17.

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Vemulapalli S, Mita A, Alvarado Y, Sankhala K, Mita M.

Target Oncol. 2011 Mar;6(1):29-39. doi: 10.1007/s11523-011-0179-4. Epub 2011 Apr 28. Review.

PMID:
21533543
18.

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.

Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M.

Invest New Drugs. 2012 Jun;30(3):1107-15. doi: 10.1007/s10637-011-9660-2. Epub 2011 Apr 15.

19.

Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.

Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M.

Clin Cancer Res. 2011 Jan 15;17(2):363-71. doi: 10.1158/1078-0432.CCR-10-1411. Epub 2011 Jan 11.

20.

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.

Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P.

Clin Cancer Res. 2010 Jun 1;16(11):3044-56. doi: 10.1158/1078-0432.CCR-09-3368. Epub 2010 May 25.

21.

Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.

Sankhala KK, Pandya DM, Sarantopoulos J, Soefje SA, Giles FJ, Chawla SP.

Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1607-14. doi: 10.1517/17425250903451675. Review.

PMID:
19929449
22.

Targeting sarcomas: novel biological agents and future perspectives.

Mahalingam D, Mita A, Sankhala K, Swords R, Kelly K, Giles F, Mita MM.

Curr Drug Targets. 2009 Oct;10(10):937-49. Review.

PMID:
19860642
23.

Review: desmoplastic small round cell tumor: current treatment approach and role of targeted therapy.

Sankhala KK, Chawla SP.

Clin Adv Hematol Oncol. 2009 Jul;7(7):476-8. Review. No abstract available.

PMID:
19701156
24.

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.

Sankhala K, Giles FJ.

Expert Rev Hematol. 2009 Aug;2(4):399-414. doi: 10.1586/ehm.09.31.

PMID:
21082945
25.

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.

Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M.

Target Oncol. 2009 Apr;4(2):135-42. doi: 10.1007/s11523-009-0107-z. Epub 2009 Apr 21. Review.

PMID:
19381454
26.

Targeting the mTOR pathway using deforolimus in cancer therapy.

Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM.

Future Oncol. 2009 Apr;5(3):291-303. doi: 10.2217/fon.09.9. Review.

PMID:
19374536
27.

Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.

Kelly K, Swords R, Kilcoyne A, Sankhala K, Mahalingam D, Padmanabhan S, Giles F.

Leuk Lymphoma. 2009 Feb;50(2):297-9. doi: 10.1080/10428190802607541. No abstract available.

PMID:
19160124
28.

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.

Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F.

Expert Opin Investig Drugs. 2008 Dec;17(12):1947-54. doi: 10.1517/13543780802556485 . Review.

PMID:
19012509
29.

Future options for imatinib mesilate-resistant tumors.

Sankhala KK, Papadopoulos KP.

Expert Opin Investig Drugs. 2007 Oct;16(10):1549-60. Review.

PMID:
17922620

Supplemental Content

Loading ...
Support Center